Focus: Lantern Pharma is an AI-driven oncology company focused on personalized cancer therapy, leveraging artificial intelligence to identify patient populations most likely to benefit from its drug candidates. The company is publicly traded (NASDAQ: LTRN) with a pipeline spanning lung cancer, breast cancer, prostate cancer, glioblastoma, and lymphomas.
Profile data last refreshed 36m ago · AI intelligence enriched 1mo ago
No open roles listed right now. Follow Lantern Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Lantern Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lantern Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Lantern Pharma Says AI Cuts First-In-Human Drug Development Cost To $2 Million-$3 Million - Pulse 2.0
Lantern Pharma Says AI Cuts First-In-Human Drug Development Cost To $2 Million-$3 Million Pulse 2.0
Lantern Pharma Says AI Cuts First-In-Human Drug Development Cost To $2 Million-$3 Million - Pulse 2.0
Lantern Pharma Says AI Cuts First-In-Human Drug Development Cost To $2 Million-$3 Million Pulse 2.0
Lantern Pharma Q2 EPS of $(0.57) misses estimate by 50% - scanx.trade
Lantern Pharma Q2 EPS of $(0.57) misses estimate by 50% scanx.trade
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - Business Wire
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine Business Wire
New AI company plans to take Lantern Pharma's platform beyond oncology - Stock Titan
New AI company plans to take Lantern Pharma's platform beyond oncology Stock Titan
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpace
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine BioSpace
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo